CA2270975A1 - Stabilized sustained release tramadol formulations - Google Patents

Stabilized sustained release tramadol formulations

Info

Publication number
CA2270975A1
CA2270975A1 CA002270975A CA2270975A CA2270975A1 CA 2270975 A1 CA2270975 A1 CA 2270975A1 CA 002270975 A CA002270975 A CA 002270975A CA 2270975 A CA2270975 A CA 2270975A CA 2270975 A1 CA2270975 A1 CA 2270975A1
Authority
CA
Canada
Prior art keywords
tramadol
sustained release
matrix
dosage form
stabilized sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002270975A
Other languages
French (fr)
Other versions
CA2270975C (en
Inventor
Benjamin Oshlack
Hua-Pin Huang
Mark Chasin
Paul Goldenheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro-Celtique, S.A.
Benjamin Oshlack
Hua-Pin Huang
Mark Chasin
Paul Goldenheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique, S.A., Benjamin Oshlack, Hua-Pin Huang, Mark Chasin, Paul Goldenheim filed Critical Euro-Celtique, S.A.
Publication of CA2270975A1 publication Critical patent/CA2270975A1/en
Application granted granted Critical
Publication of CA2270975C publication Critical patent/CA2270975C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35 ~C to about 65 ~C for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in vitro dissolution after exposure to accelerated storage conditions of at least one month at 40 ~C/75 % RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20 % of the total amount of tramadol released when compared to in vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.
CA002270975A 1997-07-02 1998-07-02 Stabilized sustained release tramadol formulations Expired - Lifetime CA2270975C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5160297P 1997-07-02 1997-07-02
US60/051,602 1997-07-02
PCT/US1998/014087 WO1999001111A1 (en) 1997-07-02 1998-07-02 Stabilized sustained release tramadol formulations

Publications (2)

Publication Number Publication Date
CA2270975A1 true CA2270975A1 (en) 1999-01-14
CA2270975C CA2270975C (en) 2003-04-01

Family

ID=21972304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002270975A Expired - Lifetime CA2270975C (en) 1997-07-02 1998-07-02 Stabilized sustained release tramadol formulations

Country Status (12)

Country Link
US (2) US6306438B1 (en)
EP (1) EP1009387B1 (en)
JP (2) JP3739410B2 (en)
AT (1) ATE322892T1 (en)
AU (1) AU8293498A (en)
CA (1) CA2270975C (en)
CY (1) CY1106112T1 (en)
DE (1) DE69834195T2 (en)
DK (1) DK1009387T3 (en)
ES (1) ES2263211T3 (en)
PT (1) PT1009387E (en)
WO (1) WO1999001111A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703189B2 (en) 2001-05-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Medicinal composition

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
ES2415876T3 (en) 1997-12-22 2013-07-29 Euro-Celtique S.A. Oral pharmaceutical dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19901683B4 (en) * 1999-01-18 2005-07-21 Grünenthal GmbH Controlled-release analgesic
CA2388560A1 (en) * 1999-08-31 2001-03-08 Grunenthal Gmbh Sustained-release form of administration containing tramadol saccharinate
CN101703777B (en) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 Tamper-resistant oral opioid agonist formulations
JP4570725B2 (en) * 2000-04-05 2010-10-27 大塚製薬株式会社 Composition for pharmaceutical preparation
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
AU2002314968B2 (en) * 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
PT1416842E (en) 2001-07-18 2009-03-31 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
KR20040029405A (en) 2001-08-06 2004-04-06 유로-셀티크 소시에떼 아노뉨 Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP2201965A1 (en) * 2001-11-08 2010-06-30 Ziscoat N.V. Intraluminal device with a coating containing a therapeutic agent
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
PT1476138E (en) * 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Modified release formulations of at least one form of tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
IL164077A0 (en) * 2002-03-22 2005-12-18 Cilag Ag Sustained release formulation of tramadol
EP3241548A1 (en) 2002-04-05 2017-11-08 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
WO2004026256A2 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
ATE400819T1 (en) * 2002-10-25 2008-07-15 Labopharm Inc CONTROLLED RELEASE PREPARATIONS
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
AR045972A1 (en) * 2002-10-25 2005-11-23 Labopharm Inc FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
CN1942175B (en) * 2002-10-25 2010-05-26 莱博法姆公司 Sustained-release tramadol formulations with 24-hour efficacy
DE10300325A1 (en) * 2003-01-09 2004-07-22 Hexal Ag Granules with oily substance, manufacturing process and tablet
KR100712356B1 (en) * 2003-01-23 2007-05-02 (주)아모레퍼시픽 Sustained-release preparations and method for producing the same
EP1905435A3 (en) 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
PL1842533T3 (en) 2003-08-06 2013-08-30 Gruenenthal Gmbh Dosage form that is secured against misuse
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
WO2006009403A1 (en) * 2004-07-22 2006-01-26 Amorepacific Corporation Sustained-release preparations containing topiramate and the producing method thereof
PT1789021E (en) 2004-08-13 2011-12-22 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
JP4971159B2 (en) 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sustained release pellet preparation containing pramipexole or a pharmaceutically acceptable salt thereof, its production method and use
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
CN101132772B (en) * 2005-01-28 2012-05-09 欧洲凯尔特公司 Alcohol resistant dosage forms
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
JP5095615B2 (en) 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Modified release of bupropion salt
AU2006269225B2 (en) 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
UA91376C2 (en) * 2005-08-24 2010-07-26 Рубикон Рисеч Пвт Лтд. Controlled release formulation
ES2620293T3 (en) 2005-09-09 2017-06-28 Paladin Labs Inc. Sustained drug release composition
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
GB2431875A (en) * 2005-10-31 2007-05-09 Alza Corp Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CN1957909B (en) * 2005-10-31 2013-09-11 阿尔扎公司 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
DK3095447T3 (en) 2006-02-03 2022-01-31 Opko Renal Llc TREATMENT OF VITAMIN D INSUFFICIENTS AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
PL2679228T3 (en) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
JP2009541423A (en) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ Combination of a cholinesterase inhibitor and a compound having affinity for 5-HT6 receptor
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
PL2481400T3 (en) 2007-04-25 2015-04-30 Opko Ip Holdings Ii Inc Oral controlled release compositions comprising vitamin D compound and waxy carrier
CN104257667B (en) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 Treat vitamin d insufficiency and shortage, secondary hyperparathyroidism and vitamin D-responsive diseases method and composition
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5774853B2 (en) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Pharmaceutical dosage form
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
MX347106B (en) 2009-03-10 2017-04-12 Euro-Celtique S A * Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
JP5667183B2 (en) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Controlled release dosage form with heat melt extrusion
ES2560210T3 (en) 2009-07-22 2016-02-17 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opiates
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2606227T3 (en) 2010-02-03 2017-03-23 Grünenthal GmbH Preparation of a pharmaceutical powder composition by an extruder
SG10201504529WA (en) * 2010-03-09 2015-07-30 Alkermes Pharma Ireland Ltd Alcohol Resistant Enteric Pharmaceutical Compositions
CN105796530A (en) 2010-03-29 2016-07-27 赛特克罗公司 Methods and compositions for reducing parathyroid levels
JP5671609B2 (en) 2010-05-10 2015-02-18 ユーロ−セルティーク エス．エイ． Pharmaceutical composition comprising hydromorphone and naloxone
WO2011141489A1 (en) * 2010-05-10 2011-11-17 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
BR112012028656A2 (en) * 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
KR20130137627A (en) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising an anionic polymer
RU2604676C2 (en) 2010-09-02 2016-12-10 Грюненталь Гмбх Destruction-resistant dosage form containing an inorganic salt
AR087359A1 (en) 2011-07-29 2014-03-19 Gruenenthal Gmbh TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO
WO2013017234A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
ES2692944T3 (en) 2012-04-18 2018-12-05 Grünenthal GmbH Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20160220512A1 (en) * 2013-09-15 2016-08-04 Rubicon Research Private Limited Modified release pharmaceutical formulations
KR102194174B1 (en) 2013-11-13 2020-12-23 유로-셀티큐 에스.에이. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (en) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3193925A2 (en) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediate release and solvent extraction inhibition modulated dosage form
FR3037789A1 (en) * 2015-06-23 2016-12-30 Rondol Ind PRODUCTION LINE FOR PRODUCTION OF MEDICAMENTS, AND PRODUCTION PLANT COMPRISING SUCH A PRODUCTION LINE
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
MX2018011820A (en) 2016-03-28 2019-01-24 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment.
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US20210308062A1 (en) * 2018-09-07 2021-10-07 R.P. Scherer Technologies, Llc Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3901968A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of methantheline
US3901969A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of methantheline
US4088798A (en) 1975-11-11 1978-05-09 Sandoz, Inc. Methods for the preparation of controlled gastric residence time medicament formulations
GB1561204A (en) 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
DE2904310A1 (en) 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh MOLDINGS WITH RETARDED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
JPS60166608A (en) 1984-02-08 1985-08-29 Japan Atom Energy Res Inst Slow-releasing composite having sandwich structure and its preparation
IE59287B1 (en) 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
US4795327A (en) 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4600645A (en) 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
IT1214629B (en) 1985-08-29 1990-01-18 Formenti Farmaceutici Spa MICRO-ENCAPSULATION PROCEDURE OF A MEDICATION, MEDICATION SO PREPARED, AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
IT1204294B (en) 1986-03-11 1989-03-01 Gentili Ist Spa METHOD OF MANUFACTURE OF GRANULARS SUITABLE FOR THE PRODUCTION OF COATED TABLETS, FOR ORAL USE, WITH CONTROLLED RELEASE
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4810501A (en) 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB8707416D0 (en) 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JP2668880B2 (en) 1987-06-23 1997-10-27 日本油脂株式会社 Method for producing coated amino acids
US5068110A (en) 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5219621A (en) 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
FR2624732B1 (en) 1987-12-21 1991-02-15 Synthelabo SUSTAINED RELEASE PHARMACEUTICAL FORMULATION
US4837033A (en) 1987-12-22 1989-06-06 Shin-Etsu Chemical Co., Ltd. Method for the preparation of a coated solid medicament
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5085866A (en) 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
CA2007055A1 (en) 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
JPH03232814A (en) 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd Production of sustained release tablet
US5077053A (en) 1990-02-12 1991-12-31 Warner-Lambert Company Zein as a moisture barrier for sugarless edible compositions and method for preparing same
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2036907C (en) 1990-02-28 1996-10-22 Yuzo Miura 3-(substituted phenyl) pyrazole derivatives, a process for producing the same, herbicidal composition containing the same and method of controlling weeds using said composition
US5178866A (en) 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
JP2558396B2 (en) 1990-06-28 1996-11-27 田辺製薬株式会社 Controlled release formulation
JPH04230625A (en) 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd Method for production of finely dispersed tablet composition consisting of microcapsule containing sprayed and dried sodium dichlofenac and having enteric coating
ZA923474B (en) 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5213811A (en) 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4329794C2 (en) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadol salt-containing drugs with delayed release
JP3232814B2 (en) 1993-09-22 2001-11-26 ジェイエスアール株式会社 Ink composition for thermal recording media
WO1995026753A1 (en) 1994-04-01 1995-10-12 Tsumura & Co. Process for producing sustained-release tablets and enteric tablets
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703189B2 (en) 2001-05-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU8293498A (en) 1999-01-25
ES2263211T3 (en) 2006-12-01
WO1999001111A1 (en) 1999-01-14
US20020102302A1 (en) 2002-08-01
US6645527B2 (en) 2003-11-11
JP2004002419A (en) 2004-01-08
ATE322892T1 (en) 2006-04-15
DE69834195T2 (en) 2007-03-29
CA2270975C (en) 2003-04-01
US6306438B1 (en) 2001-10-23
EP1009387A1 (en) 2000-06-21
EP1009387A4 (en) 2004-08-25
DE69834195D1 (en) 2006-05-24
JP2000510487A (en) 2000-08-15
EP1009387B1 (en) 2006-04-12
DK1009387T3 (en) 2006-08-14
PT1009387E (en) 2006-08-31
JP3739410B2 (en) 2006-01-25
JP4576097B2 (en) 2010-11-04
CY1106112T1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
CA2270975A1 (en) Stabilized sustained release tramadol formulations
IL119684A (en) Long lasting release nifedipine preparation in form of press coated tablets
AU4930197A (en) Improved rapidly disintegratable multiparticulate tablet
BG102228A (en) Medicamentous form with controlled release of slightly soluble medicamentous substances
CA2346001A1 (en) Controlled release nanoparticulate compositions
IL111400A0 (en) Pharmaceutical compositions containing metroprolol and methods for the preparation thereof
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
NO881296D0 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATION.
KR950703935A (en) Pharmaceutical compositions that block taste
CA2016039A1 (en) Extended release pharmaceutical formulations
IL113325A (en) Controlled release metoprolol oral composition containing heteropolysaccaride and a method for the preparation thereof
SE8505099L (en) POWDER WITH REGULATED RELEASE AND SET FOR MANUFACTURING THEREOF
ES512393A0 (en) "A PROCEDURE FOR PREPARING A PHARMACEUTICAL LIBERATION COMPOSITION MAINTAINED ON THE BASIS OF MICRONIZED INDORAMIN".
DK0620731T3 (en) Pharmaceutical composition in the form of a shower and / or decay tablet or instant granule and method of preparation thereof
EP0103387A3 (en) Long-acting matrix tablet formulations
CA2339913A1 (en) Pharmaceutical formulations and method for making
CA2194610A1 (en) Sustained-Release Formulation of Animal Growth Hormone and Process for Preparation Thereof
TW430561B (en) Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
DE69634080D1 (en) MEANS OF PREVENTING THE TURNING OF THE FRONT LENS CAPSULE
DE4333190C2 (en) Bite-coated tablet with delayed release of active ingredient
WO1999042087A3 (en) Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content
EP0093538A1 (en) Sustained release lithium-containing tablets and method for their manufacture
ZA892871B (en) Microbeads of ditiazem a process for their manufacture and a sustained-release pharmaceutical composition containing them
IT1317871B1 (en) Controlled release and taste masking oral compositions comprising active ingredient incorporated in a matrix structure

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180703